AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06609993
Drug: postoperative rescue opioid analgesia using morphine
RxNorm normalized name: OPIOID ANALGESICS
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
Trial: NCT03638856
Drug: Misoprostol 200Mcg Tab
RxNorm normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
Trial: NCT00239629
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00239629
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT03483077
Drug: BI 730460
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01307579
Drug: Caspofungin Acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01307579
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV or PO
Trial: NCT02076100
Drug: Ruzasvir
RxNorm normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
Trial: NCT01406860
Drug: Droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
Trial: NCT01406860
Drug: Metoclopramide + diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
Trial: NCT03396276
Drug: Suboxone
RxNorm normalized name: Suboxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8mg of buprenorphine/2mg of naloxone
Trial: NCT04657068
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.
Trial: NCT04657068
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.
Trial: NCT02364453
Drug: PACAP38
DrugBank: PACAP38 (DB17073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
Trial: NCT01286974
Drug: ABT-869, linifanib
DrugBank: Linifanib (DB06080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linifanib once a day (QD), oral tablet
Trial: NCT03988374
Drug: Dentifrices
RxNorm normalized name: DENTIFRICES
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice on plaque, gingivitis, and bleeding.
Trial: NCT00016601
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00016601
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00016601
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00016601
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00016601
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00016601
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00535756
Drug: Creon
RxNorm normalized name: Creon
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
Trial: NCT01142232
Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
Trial: NCT01142232
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
Trial: NCT02697071
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Trial: NCT02256696
Drug: PA-824
RxNorm normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg QD
Trial: NCT02256696
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg QD
Trial: NCT02256696
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg QD
Trial: NCT02256696
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/kg QD
Trial: NCT02256696
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg/kg QD
Trial: NCT02256696
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg QD
Trial: NCT01848171
Drug: L-thyroxine
RxNorm normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02423226
Drug: Systemic chemotherapy (FOLFIRI)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Trial: NCT01534143
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00203138
Drug: rasagiline mesylate
RxNorm normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01534143
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01534143
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01534143
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01534143
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT03022253
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV
Trial: NCT01467726
Drug: Velusetrag
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT00698945
Drug: Istalol and Optive
RxNorm normalized name: Istalol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
Trial: NCT00698945
Drug: Alphagan
RxNorm normalized name: Alphagan
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alphagan: two drops a day for 28 days
Trial: NCT01262677
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
Trial: NCT01262677
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
Trial: NCT01262677
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
Trial: NCT01262677
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
Trial: NCT01262677
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
Trial: NCT03805347
Drug: Helminthostachys zeylanica(L.)Hook
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
Trial: NCT03805347
Drug: Starch
RxNorm normalized name: Starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch in capsule, 1gm/time, 3 times daily
Trial: NCT01016678
Drug: Treximet
RxNorm normalized name: Treximet
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
Trial: NCT01212263
Drug: Clomiphine citrate plus low dose uFSH
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
Trial: NCT00615602
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
Trial: NCT00615602
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
Trial: NCT00615602
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Trial: NCT00615602
Drug: Granulocyte-colony stimulating growth factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Trial: NCT00615602
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
Trial: NCT02295553
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03491969
Drug: Alpha-Lipoic Acid(α-LA)
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, po, tid
Trial: NCT02786043
Drug: Propionyl-L-Carnitine Hydrochloride
RxNorm normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
Trial: NCT02295553
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00285428
Drug: hA20-humanized anti-CD20 antibody
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once weekly iv dosing for 4 weeks
Trial: NCT00828477
Drug: Xibrom
RxNorm normalized name: Xibrom
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xibrom: two times a day for seven days in the first eye.
Trial: NCT00828477
Drug: Nevanac
RxNorm normalized name: Nevanac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevanac: three times a day for seven days in the second eye.
Trial: NCT02279628
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
Trial: NCT02279628
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
Trial: NCT00169078
Drug: Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00056992
Drug: ADI-PEG 20
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02508220
Drug: Syntocinon
RxNorm normalized name: Syntocinon
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray
Trial: NCT00688883
Drug: Fludarabine Phosphate (Fludara)
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
Trial: NCT01171807
Drug: Dex 21-P
RxNorm normalized name: Dex
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.
Trial: NCT04860076
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care
Trial: NCT04294953
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
Trial: NCT00044265
Drug: ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00252837
Drug: Tesaglitazar
RxNorm normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02957851
Drug: Medical Air
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02957851
Drug: EMONO
RxNorm normalized name: Lemonol
DrugBank: 3'-Uridinemonophosphate (DB02714)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03825445
Drug: GnRHa (Fertipeptil 0.1mg)
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
Trial: NCT03057990
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
Trial: NCT04610541
Drug: Remdesivir-HU
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir-HU 100 mg concentrate for solution for infusion
Trial: NCT02486276
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT02486276
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT03170895
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
Trial: NCT03170895
Drug: Omacetaxine Mepesuccinate Injection
RxNorm normalized name: omacetaxine mepesuccinate Injection
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
Trial: NCT00446043
Drug: Adapalene/Benzoyl Peroxide
RxNorm normalized name: ADAPALENE/BENZOYL PEROXIDE
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
Trial: NCT02969239
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Trial: NCT03585270
Drug: Clazosentan
RxNorm normalized name: clazosentan
DrugBank: Clazosentan (DB06677)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Clazosentan will be administered as a continuous intravenous infusion at the dose of 15 mg/hour for up to 14 days.
Trial: NCT00194935
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03588130
Drug: Gel Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm
Trial: NCT03167242
Drug: Coartem
RxNorm normalized name: Coartem
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coartem comes as 20/120 mg dispersible tablets or 80/480 mg tablets for oral administration. Coartem was administered twice daily for 3 days as active comparator.
Trial: NCT03167242
Drug: Lumefantrine Solid Dispersion Formulation
RxNorm normalized name: Lumefantrine
DrugBank: Lumefantrine (DB06708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LUM-SDF comes in 240 mg or 480 mg sachets for oral administration. LUM-SDF was administered in combination with KAF156 once daily (QD) for 1, 2 or 3 days at 480 mg or 960 mg doses.
Trial: NCT04398290
Drug: Nitrogen gas
RxNorm normalized name: nitrogen Gas for Inhalation
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mcg/kg ideal body weight (IBW)/hour
Trial: NCT04398290
Drug: Oxygen gas
RxNorm normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen administered via nasal cannula
Trial: NCT02093000
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
Trial: NCT00467142
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes